CJC-1295 with Ipamorelin: Research Overview

In growth hormone-related peptide research, the combination of CJC-1295 with Ipamorelin is a widely referenced dual-peptide protocol examined for its effects on the endocrine system. Researchers investigating growth hormone axis modulation frequently examine these two peptides together because they interact with the GH release system through distinct but complementary mechanisms — one acting as a GHRH analogue and the other as a Growth Hormone Releasing Peptide (GHRP).

This article provides a comprehensive research overview of CJC1295 with Ipamorelin, covering the individual properties of each peptide, the scientific rationale for studying them in combination, and what published research suggests about their combined biological activity.

Understanding the Two Peptides

CJC-1295: The GHRH Analogue

CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) — the hypothalamic hormone that signals the anterior pituitary to produce and release growth hormone. As a GHRH analogue, CJC-1295 acts on GHRH receptors on pituitary somatotroph cells to stimulate GH production.

For research purposes, CJC-1295 is available in two variants:

• CJC-1295 with DAC: albumin-binding modification, half-life approximately 6–8 days, weekly or bi-weekly administration in research protocols
• CJC-1295 without DAC (Modified GRF 1-29): no albumin binding, half-life approximately 30 minutes, mimics pulsatile GH release

When used in combination with Ipamorelin, most research protocols employ CJC-1295 without DAC because its shorter half-life better aligns with the pulsatile GH secretion pattern that Ipamorelin also produces. For a full overview of CJC-1295 alone, see Article 5: CJC-1295 Peptide: DAC vs No-DAC Research Guide.

Ipamorelin: The GHRP

Ipamorelin is a synthetic pentapeptide (5 amino acids) belonging to the Growth Hormone Releasing Peptide (GHRP) class. Unlike CJC-1295, which acts on GHRH receptors, Ipamorelin is a ghrelin receptor agonist — it binds to the growth hormone secretagogue receptor (GHS-R) on pituitary cells.

Key research characteristics of Ipamorelin:

• 5 amino acid pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)
• Ghrelin receptor agonist (GHS-R1a agonist)
• Highly selective for GH release — does not significantly stimulate cortisol or prolactin in research models
• Biological half-life: approximately 2 hours
• Produces pulsatile GH release in laboratory models

Ipamorelin’s selectivity for GH release — with minimal effect on other hormonal axes — makes it one of the most studied GHRPs in research settings. Its clean GH-stimulating profile is one reason it is frequently paired with CJC-1295 in combined research protocols.

Why Researchers Study CJC-1295 with Ipamorelin Together

The scientific rationale for studying CJC-1295 with Ipamorelin as a combined research protocol is grounded in the complementary mechanisms of the two peptides:

Dual Receptor Activation

CJC-1295 and Ipamorelin activate different receptor systems on pituitary somatotroph cells. CJC-1295 binds GHRH receptors while Ipamorelin binds GHS-R receptors. When both receptors are activated simultaneously, research models have demonstrated a synergistic amplification of GH release that exceeds the effect of either peptide alone.

This synergistic GH release occurs because the two signalling pathways converge on the same downstream effectors within pituitary cells — both ultimately stimulate the adenylyl cyclase and phospholipase C pathways that trigger GH secretion — but they do so via independent receptor systems. Activating both pathways simultaneously produces a stronger combined signal than activating either alone.

Complementary Half-Lives

When CJC-1295 without DAC is used alongside Ipamorelin, both peptides have relatively short half-lives of 30 minutes and 2 hours respectively. This alignment means they can be administered together at the same time points in a research protocol, producing a coordinated, pulsatile GH release event that mirrors the natural GH secretion rhythm observed in biological systems.

Preserved GH Selectivity

Because Ipamorelin is highly selective for GH release and does not significantly stimulate cortisol or prolactin in research models, the CJC-1295 with Ipamorelin combination allows researchers to study robust GH axis stimulation without the confounding effects of other hormonal changes. This selectivity makes it easier to isolate the specific effects of GH axis modulation in laboratory models.

Research Applications of CJC-1295 with Ipamorelin

Growth Hormone Axis Research

The primary application of the CJC1295 Ipamorelin combination is in research examining the hypothalamic-pituitary-GH axis. Laboratory models use this combination to study how synergistic receptor stimulation influences GH pulse amplitude, frequency, and overall secretion volume.

IGF-1 and Anabolic Pathway Research

Growth hormone released in response to CJC-1295 and Ipamorelin stimulates hepatic production of IGF-1. Researchers studying anabolic signalling pathways, protein synthesis, and muscle cell biology frequently use this combination to stimulate the GH/IGF-1 axis in controlled models.

Metabolic and Adipose Tissue Research

GH is a key lipolytic hormone — it stimulates the breakdown of triglycerides in adipose tissue. Laboratory models examining metabolic regulation and body composition frequently incorporate CJC-1295 with Ipamorelin to study the effects of sustained GH axis stimulation on adipose biology and metabolic parameters.

Age-Related Endocrine Research

Given that GH secretion declines significantly with age, some research models studying age-related endocrine changes use CJC-1295 with Ipamorelin to modulate the GH axis and examine downstream effects in aged biological systems.

Research Protocol Considerations

Researchers designing protocols with CJC-1295 and Ipamorelin should consider the following parameters commonly referenced in published literature:

• Both peptides administered together at the same time point for synergistic GH stimulation
• Administration typically timed to coincide with natural GH pulses — often late evening in circadian research models
• CJC-1295 without DAC: commonly studied at 100 mcg per administration in published models
• Ipamorelin: commonly studied at 100–200 mcg per administration in published models
• Protocol duration in published research: typically 8–16 weeks
• GH and IGF-1 levels are the primary biomarkers measured in most research protocols

CJC-1295 with Ipamorelin vs CJC-1295 DAC with Ipamorelin

Researchers sometimes question whether to use CJC-1295 DAC or No-DAC when pairing with Ipamorelin. Both approaches have been studied, but they produce different GH release patterns:

• CJC-1295 No-DAC + Ipamorelin: both peptides have short half-lives, producing coordinated pulsatile GH release when co-administered. Mimics natural GH secretion rhythm more closely.
• CJC-1295 DAC + Ipamorelin: CJC-1295 DAC provides sustained background GHRH stimulation over 6–8 days, while Ipamorelin is used separately to produce additional GH pulses. These are effectively two independent protocols rather than a true synchronised combination.

Most combined CJC-1295 with Ipamorelin research protocols use the No-DAC variant for its pulsatile compatibility with Ipamorelin’s shorter half-life. For detailed coverage of the DAC variant, see Article 5.

Sourcing CJC-1295 and Ipamorelin for Research

Meta Molecule provides both CJC-1295 and Ipamorelin as high-purity research peptides, with full batch-specific Certificates of Analysis available on our COAs page. Both compounds are available in lyophilised vial format for laboratory use.

Registration is required to access and order from the Meta Molecule research catalog.

Frequently Asked Questions: CJC-1295 with Ipamorelin

Q: Why do researchers study CJC-1295 with Ipamorelin together?

A: CJC-1295 and Ipamorelin activate different receptor systems on pituitary cells — GHRH receptors and GHS-R receptors respectively. Simultaneously activating both systems produces a synergistic amplification of growth hormone release in laboratory models that exceeds what either peptide achieves individually.

Q: Should CJC-1295 DAC or No-DAC be used with Ipamorelin?

A: Most combined research protocols use CJC-1295 without DAC (Modified GRF 1-29) alongside Ipamorelin, because the shorter half-lives of both peptides align well for co-administration producing pulsatile GH release. CJC-1295 DAC has a much longer half-life that produces a different release pattern when combined with Ipamorelin.

Q: Is Ipamorelin a GHRP?

A: Yes. Ipamorelin is a Growth Hormone Releasing Peptide (GHRP) and a selective ghrelin receptor agonist. It stimulates pituitary GH release without significantly affecting cortisol or prolactin levels in laboratory research models, making it one of the most selective GHRPs studied.

Q: How does the CJC-1295 and Ipamorelin combination compare to using Sermorelin?

A: Sermorelin is an older GHRH analogue with a shorter half-life than CJC-1295. While some researchers use Sermorelin in combination with GHRPs, CJC-1295 offers superior enzymatic stability and, in the DAC form, a dramatically extended half-life. The CJC-1295 with Ipamorelin combination is generally considered to produce more robust and controllable GH stimulation in research models.

Q: Where can I source CJC-1295 and Ipamorelin for laboratory research?

A: Meta Molecule offers both CJC-1295 and Ipamorelin as high-purity research peptides with third-party batch Certificates of Analysis. Registration is required to access our full research product catalog.

DISCLAIMER – This article is intended for educational and informational purposes related to biochemical and laboratory research. The information provided does not constitute medical advice and is not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA. Research peptides are intended solely for laboratory study by professional researchers and are not intended for human consumption